• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 21, 2018

View Archived Issues

Dendreon seeks expanded role for Provenge in new early stage prostate cancer trial

The transnational Lazarus tale of Provenge (sipuleucel-T), a pioneering cellular immunotherapy from Dendreon Pharmaceuticals LLC, is opening what could be a significant new chapter with the initiation of a trial designed to prove the treatment can halt prostate cancer progression, reducing or delaying the need for definitive therapies such as surgery and radiation. Expected to begin enrolling later this year, top-line data from the study are due by 2023. Read More

Post-Aimovig, CGRP space takes stock as three more line the migraine runway

Amgen Inc. having scored the first of four expected approvals in the calcitonin gene-related peptide (CGRP) receptor class with Aimovig (erenumab) for preventing migraine, Wall Street set about handicapping odds for the others in a large market. Read More

WHO ramps up Ebola vaccination, containment measures in the Congo

DUBLIN – The current Ebola outbreak in the Democratic Republic of the Congo (DRC), which by last Thursday had claimed 25 lives, is not yet sufficiently alarming to trigger "a public health emergency of international concern," the World Health Organization concluded Friday. So far, 45 cases have been reported, 14 of which have been confirmed by laboratory testing. Three of the cases involved health workers. Read More

$40M series A places 'Accent' on cancer using epitranscriptomics

Accent Therapeutics Inc.formally launched with a $40 million series A and a platform built around epitranscriptomics – the field referring to RNA-modifying proteins (RMPs) that control many aspects of RNA biology – to pursue precision cancer therapies. The investment syndicate included the Column Group, Atlas Venture and Ecor1 Capital. Read More

Cysteine in KRAS-G12C is its own downfall

Weak binding to a shallow pocket is not what most drug developers would consider characteristics of a viable drug lead, let alone a desirable one. Read More

Chia Tai Tianqing's kinase inhibitor wins approval in China for 3rd-line NSCLC

HONG KONG – China's Chia Tai Tianqing Pharmaceutical Holdings Co. Ltd. gained marketing approval for its first innovative treatment for advanced non-small-cell lung cancer (NSCLC), which has the potential of becoming a standard third-line treatment for the disease. Read More

Financings

Ligand Pharmaceuticals Inc., of San Diego, has priced $650 million worth of 0.75 percent convertible senior notes due 2023 in a private offering to qualified institutional buyers. Read More

Other news to note

Histoindex Pte. Ltd., of Singapore, said it is collaborating with Cymabay Therapeutics Inc., of Newark, Calif., to evaluate the efficacy of seladelpar in a phase IIb study of 175 subjects with biopsy-confirmed nonalcoholic steatohepatitis (NASH). Read More

Clinical data for May 18, 2018

Read More

Regulatory actions for May 18, 2018

Read More

Bench Press: BioWorld looks at Translational Medicine

Targeted complement inhibition was able to reduce inflammation and prevent the immune system from finishing off stressed neurons after stroke. The complement system is a part of the innate immune system, and one of its roles is to mark neuronal debris for cleanup in the brain. Read More

Record-hitting series A funding redefines early science

Barely five months into 2018, investors have placed more seed and series A money into biotherapeutics companies than all of last year. At this pace, the $2.6 billion raised could translate to more than $6 billion by year's end – more than double the amounts logged for the two highest years on record, 2015 and 2016. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe